About us
- About us
- Team
- Investors
Technology
Pipeline
- Pipeline
- About AMD
- PST-611
- PST-809
News & Events
Contact

Month: April 2025

PulseSight Therapeutics: Nonviral Gene Therapy for Dry AMD

Posted on April 16, 2025January 15, 2026 by edgover

PulseSight Therapeutics: Nonviral Gene Therapy for Dry AMD

Posted in In the news

Search

Recent Posts

PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy
EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)
Judith Greciet on Targeting Iron Dysregulation: PulseSight’s Next-Generation Approach to Geographic Atrophy
PulseSight Therapeutics Reports P-I (PST-611-CT1) Trial Data on PST-611 in Dry AMD/Geographic Atrophy
PulseSight Reports Phase 1 GA Data

Recent Comments

No comments to show.

Archives

October 2026
September 2026
August 2026
May 2026
April 2026
January 2026
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
February 2025
January 2025
November 2024
October 2024
September 2024
August 2024
April 2024
March 2024
February 2024

Categories

In the news
Press release

CONTACT US

PRIVACY POLICY

DISCLAIMER

© 2026 PULSESIGHT THERAPEUTICS ALL RIGHTS RESERVED